World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
45604
World Ranking
12919
National Ranking
6604

Manish A. Shah publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Manish A. Shah sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 442 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Manish A. Shah D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Manish A. Shah sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Manish A. Shah is affiliated with Cornell University in the United States and has contributed extensively to research in medicine, with a particular focus on oncology. Their work spans a wide range of subfields including oncology, pulmonary and respiratory medicine, surgery, molecular biology, and pathology and forensic medicine.

The scientist's research primarily centers on cancer treatment and management, with notable emphasis on gastric cancer, esophageal cancer, cancer immunotherapy, colorectal cancer, lung cancer, pancreatic and hepatic oncology, and studies on barrier structure and function.

Frequent coauthors in Manish A. Shah's collaborative network include Peter C. Enzinger, Kohei Shitara, Florian Lordick, Eric Van Cutsem, and Jaffer A. Ajani.

Manish A. Shah's publication record features numerous papers in leading venues, with significant contributions in journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Future Oncology

Their recent papers include:

  • Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study, 2021, The Lancet
  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer, 2020, Journal of Clinical Oncology
  • Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet
  • Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial, 2023, Nature Medicine
  • Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline, 2020, Journal of Clinical Oncology

The topics addressed in their work include:

  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Pancreatic and Hepatic Oncology Research
  • Barrier Structure and Function Studies

Best Publications

  • A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

    Marcy E. MacDonald;Christine M. Ambrose;Mabel P. Duyao;Richard H. Myers

  • A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

    M Shah;N Datson;L Srinidhi;VP Stanton

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

    Ki Young Chung;Jinru Shia;Nancy E. Kemeny;Manish Shah

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

    Jong-Mu Sun;Lin Shen;Manish A Shah;Peter Enzinger

  • Targeting the Cell Cycle: A New Approach to Cancer Therapy

    Gary K. Schwartz;Manish A. Shah

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Takashi Kojima;Manish A Shah;Kei Muro;Eric Francois

  • Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

    Holly G. Prigerson;Yuhua Bao;Manish A. Shah;M. Elizabeth Paulk

  • Gastric cancer epidemiology and risk factors.

    Douglas E. Guggenheim;Manish A. Shah

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

    Manish A. Shah;Gary K. Schwartz

  • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

    Peter C. Thuss-Patience;Manish A. Shah;Atsushi Ohtsu;Eric Van Cutsem

  • Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

    Manish A. Shah;Takashi Kojima;Daniel Hochhauser;Peter Enzinger

  • Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

    Josep Tabernero;Paulo M. Hoff;Lin Shen;Atsushi Ohtsu

  • Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

    Y.Y. Janjigian;D. Werner;C. Pauligk;K. Steinmetz

  • Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram.

    Vivian E. Strong;Kyo Young Song;Cho Hyun Park;Lindsay M. Jacks

  • Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Edward P. Balaban;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

Frequent Co-Authors

David P. Kelsen
David P. Kelsen Memorial Sloan Kettering Cancer Center
Laura H. Tang
Laura H. Tang Memorial Sloan Kettering Cancer Center
Daniel G. Coit
Daniel G. Coit Memorial Sloan Kettering Cancer Center
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Mithat Gonen
Mithat Gonen Memorial Sloan Kettering Cancer Center
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center
Murray F. Brennan
Murray F. Brennan Memorial Sloan Kettering Cancer Center
Toshihiko Doi
Toshihiko Doi Okayama University
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways to a medical career? Online healthcare programs offer flexible options for students with different educational backgrounds. Many nursing professionals are now considering programs like the rn to bsn without clinicals, designed for registered nurses seeking to advance their qualifications without traditional in-person requirements.

For those aiming for leadership or advanced clinical roles, accredited accelerated dnp programs provide an efficient route to a Doctor of Nursing Practice. These programs are often available fully online, with some featuring manageable timelines and reduced on-campus commitments.

If convenience and speed are major concerns, look into comprehensive dnp programs online that cater to working professionals. Meanwhile, those eager to enter healthcare sooner can consider fast track medical lpn programs, delivering essential skills quickly and efficiently.

These online degree options make it easier than ever to start or advance a career in medicine, helping you achieve your goals while balancing work and life commitments.

Best Scientists Citing Manish A. Shah

Trending Scientists